- News & insights/
- Consilium news/
- Consilium advises 30 Technology on up to £176 million divestment of...
18 May 2023
Consilium advises 30 Technology on up to £176 million divestment of wound care division to Convatec
London, 18 May 2023, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported 30 Technology on the sale of its wound care division to Convatec Group Plc (LSE: CTEC) for up to £176 million.
The sale encompasses all wound care assets, research and development and commercial applications of its antimicrobial nitric oxide (NO) technology related to the topical treatment of chronic and acute wounds, burns and tissue repair, as well as other certain medical device applications.
This strategic divestment will pave the way for 30 Technology to advance its platform of NO-generating technologies, tackling critical unmet needs in respiratory disease, animal health, rare diseases, oral health, ophthalmology, and a range of other therapeutics applications, each of which constitute billion-dollar market opportunities.
30 Technology's lead respiratory products are inhaled solutions based upon their patented NO-generating formula, which produces potent antimicrobial concentrations of NO directly at the site of infection. 30 Technology believes that these assets will be effective, even against severe antimicrobial- resistant bacteria.
NO is critical to immunity, tissue healing and blood oxygenation, and 30 Technology is the first to successfully develop and patent a novel platform technology that can safely deliver high-dose nitric oxide for sustained periods in multiple different forms.
“30 Technology has created a platform with a clear pathway in numerous applications. Its successful divestment of its wound care business to Convatec is a clear validation of the approach the company has taken so far,” said Amber Fennell, Partner at Consilium Strategic Communications. “Our focus was quickly getting to grips with the 30 Technology story and its innovation in the nitric oxide space and communicating that internationally. We look forward to supporting the company going forward.”
Syd Hanna, Group Executive Director of 30 Technology, commented: “We were in close communication with Consilium from the outset, who provided timely advice and important input on how to communicate the news. The excellent press coverage we received is testament to their hard work.”
The Consilium team representing 30 Technology on the divestment was Amber Fennell, Chris Welsh, Ashley Tapp, Lucy Featherstone and Evi Useh.
To view 30 Technology’s announcement, please visit: https://30.technology/30-technologys-platform-acquired-by-convatec-group-plc/
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in Europe and the US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision-makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information, please see www.consilium-comms.com